BloombergLean L·
Dexcom’s Bet Beyond Diabetes
Dexcom CEO Jake Leach joined Bloomberg Open Interest to explain why continuous glucose monitors are becoming much bigger than diabetes devices. He says GLP-1 drugs are actually boosting CGM adoption and defends the company’s growth outlook. He also lays out Dexcom’s push into mainstream metabolic health and wellness. (Source: Bloomberg)
Read at Bloomberg →
